Bleakley Financial Group LLC Boosts Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Bleakley Financial Group LLC grew its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 2.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,767 shares of the medical device company’s stock after purchasing an additional 119 shares during the quarter. Bleakley Financial Group LLC’s holdings in Cooper Companies were worth $636,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of COO. Benjamin F. Edwards & Company Inc. boosted its stake in Cooper Companies by 248.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock worth $25,000 after purchasing an additional 174 shares during the last quarter. Innealta Capital LLC purchased a new stake in shares of Cooper Companies in the second quarter valued at approximately $25,000. Covestor Ltd increased its holdings in shares of Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 208 shares during the last quarter. Crewe Advisors LLC lifted its position in Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after buying an additional 252 shares in the last quarter. Finally, Tortoise Investment Management LLC boosted its stake in Cooper Companies by 75.4% during the second quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock worth $34,000 after buying an additional 169 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Insider Activity

In related news, COO Daniel G. Mcbride sold 114,992 shares of Cooper Companies stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the sale, the chief operating officer now directly owns 44,696 shares in the company, valued at $4,714,534.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Agostino Ricupati sold 1,601 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total transaction of $172,956.03. Following the completion of the sale, the chief accounting officer now owns 4,818 shares in the company, valued at $520,488.54. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Daniel G. Mcbride sold 114,992 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the sale, the chief operating officer now directly owns 44,696 shares of the company’s stock, valued at $4,714,534.08. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 256,373 shares of company stock worth $27,637,427. Corporate insiders own 2.00% of the company’s stock.

Cooper Companies Stock Down 1.4 %

COO stock opened at $106.72 on Tuesday. The Cooper Companies, Inc. has a fifty-two week low of $75.93 and a fifty-two week high of $112.38. The company’s 50 day moving average price is $104.28 and its 200 day moving average price is $96.42. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The firm has a market capitalization of $21.25 billion, a price-to-earnings ratio of 62.78, a PEG ratio of 2.56 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. Cooper Companies’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.84 EPS. On average, equities research analysts anticipate that The Cooper Companies, Inc. will post 3.65 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $115.00 target price (up from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Wells Fargo & Company raised their price target on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a report on Thursday, August 29th. Robert W. Baird boosted their price objective on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, August 29th. Finally, Piper Sandler raised their target price on Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and an average target price of $115.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.